Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac’s AADx Gene Expression Marker Attracts Significant Commercial Interest from Pharma

Published: Thursday, June 26, 2014
Last Updated: Thursday, June 26, 2014
Bookmark and Share
Evaluation in colorectal, breast and lung cancer to follow.

The Almac Group Ltd has announced plans to make its ALM AADx assay - a gene expression test developed by its Diagnostics Business Unit - available for clinical use in 2015.

Further validation of the test in ovarian cancer is on track for completion by the end of this year following the first validated results for a patient cohort, unveiled last month at ASCO’s annual meeting.

Following this meeting, Almac has experienced a significant volume of enquiries from Pharma companies seeking to develop companion diagnostics strategies.

The test, once clinically available, should have a revolutionary and highly beneficial impact for ovarian cancer patients, demonstrating likely treatment outcomes, which will enable personalized care plans and provide clinicians with better data to prescribe appropriate drug regimens.

In some patients, the use of certain drugs may produce adverse outcomes and this test will help to better identify these cohorts and potentially improve life expectancy.

Almac is currently engaged with the FDA to ensure that this assay is brought to the market in a timely manner with the appropriate regulatory approval in place.

Almac’s announcement comes ahead of this year’s BIO International Convention in San Diego (23-26 June) where the company will be unveiling their intention - alongside Arlene Foster, Northern Ireland’s Minister of Enterprise, Trade and Investment - to bring this technology to the global healthcare market to improve the management of ovarian cancer patients initially but to also transition into other cancer types.

Professor Paul Harkin, President and Managing Director of Almac’s Diagnostic Business Unit commented: “Almac is delighted to be taking a prominent position in the industry’s drive to develop novel, ground-breaking biomarkers and companion diagnostics that meet the gaps and pressing needs of the market. Indeed, we are pleased with the successful development of our AADx test and very much look forward to bringing it to the market for clinical use in ovarian cancer next year, and are confident of validating its applicability to a range of other cancer types.”

The results, already presented at ASCO 2014 in Chicago by Professor Gourley, identified a molecular subgroup of high grade serous ovarian cancer (HGSOC) patients - defined by the absence of angiogenesis and representing 40% of the HGSOC population - that showed good prognosis following standard of care chemotherapy.

However, these patients also exhibited a worse progression free and overall survival following the addition of bevacizumab within the ICON7 study translational dataset. By contrast, patients whose tumours fell outside of this molecular subgroup, exhibited a trend towards improved progression free survival.

The work was carried out in collaboration with the Medical Research Council in the UK. This key discovery marks the emergence of Almac as a major player in personalized medicine and in particular as a leader in the development and validation of the next generation of multiplex companion diagnostic (MCDx) tests.

Almac is confident that the test will work both for other anti-angiogenic compounds, functioning in a similar manner, as well as for other cancer types. The company has now engaged actively with the FDA & European Regulatory Authorities and aims to obtain both FDA Approval for the US and CE-IVD marking in Europe to bring this novel AADx assay to market in 2015.

Alastair Hamilton, Chief Executive of Invest Northern Ireland, remarked: “We are very pleased that Almac is playing such a leading role in the discovery and development of novel companion diagnostic tests for cancer treatment. This is a prime example of how investment in research and development can lead to commercial and export opportunities.

He continued: “We have supported Almac over the years as it has invested in R&D, and it is great to see the company grow and get recognized on the world stage as a leading diagnostics company. I wish the company continued success as it becomes a world leader in such a global marketplace.”

Alan Armstrong, CEO, Almac Group commented: “We are delighted to be contributing our scientific expertise and know-how to the discovery and development of new biomarkers and companion diagnostics that make a real difference to healthcare and the treatment of diseases such as ovarian cancer. Indeed, we are thrilled with the success to date of our AADx assay and look forward to enabling clinicians and patients to benefit from the test through its clinical use in 2015 and beyond.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QuickSTAT Partners with Almac Group
Strategic partnership provides JIT global logistics inventory management program and newly commissioned facility to accelerate delivery of clinical trial supplies.
Thursday, November 12, 2015
Almac Group Drives Biocatalysis Leadership with a Further $7M Investment
The investment will help develop biocatalysts for scale-up chemistry.
Friday, February 20, 2015
Almac and ESMS Global Collaborate to Offer Unique Clinical Trial Support
Sponsors requesting 24/7 medical support & emergency unblinding can save time and money.
Friday, November 28, 2014
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Thursday, November 13, 2014
Almac Introduce Flexible Clinical Trial Direct to Patient Solution
Available for clinical studies conducted throughout the US & Canada.
Friday, October 31, 2014
Almac Expand its UK Commercial Packaging Facility
Company makes further significant co-investment to meet Japanese client demand for humidity controlled blister packaging.
Friday, October 10, 2014
Almac Forms Academia-Industry Collaboration
Collaboration aims to bring a novel chemical produced via an enzymatic route from under-utilised natural oil to the market.
Friday, September 19, 2014
Almac Profits Up 30%
Company will open a new clinical trial secondary packaging facility in Singapore.
Wednesday, May 28, 2014
Almac’s Diagnostics Business Unit Receives NY State Clinical Laboratory Permit
The Permit for trial enrichment and companion diagnostics development allows them to receive patient samples for clinical testing in New York.
Tuesday, April 15, 2014
Almac Achieves Double Success at Business Award Ceremony
Presented with both Excellence in Innovation & Technology.
Tuesday, April 01, 2014
Almac Expands Asia Pacific Operations
Comprehensive support for trials of any size or complexity whether they originate in Asia or include Asian sites.
Wednesday, March 12, 2014
Almac Wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
The awards held to recognize the success and achievements of Ireland’s internationally renowned scientists.
Thursday, December 12, 2013
Almac Announces Release of Enhanced 3PL Customer Billing Application
Company further enhance 3rd Party Logistics commercial support services for niche / orphan drugs.
Tuesday, November 19, 2013
Almac Increase Global Stability Storage Capacity
Company has completed a $2m investment programme.
Tuesday, November 05, 2013
Richard Segiel, Jr. Joins Almac as Vice President of US Business Development
Richard will focus on developing new business, maintaining existing business, and developing partnerships.
Wednesday, October 30, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!